Tecentriq (atezolizumab) 1,200 mg/20 mL, 1 vial, F. Hoffmann-La Roche, Switzerland, original Tecentriq (atezolizumab) is used for approved cancer indications including urothelial carcinoma. Medicine delivery from Europe within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.

Urothelial carcinoma:

Treatment of adult patients with locally advanced or metastatic urothelial cancer:

• For those who are not suitable for cisplatin-containing chemotherapy and whose tumor expresses PD-L1 (immune cells stained with PD-L1 infiltrating the tumor and covering ≥ 5% of the tumor area), or
• For those who are not suitable for any platinum-containing chemotherapy, regardless of the tumor's level of PD-L1 expression.

Non-cell lung cancer (NSCLC):

First-line treatment as monotherapy for adult patients with metastatic non-CBLC lung cancer (NSCLC) with high PD-L1 expression (PD-L1-stained tumor cells ≥ 50% or stained immune cells infiltrating the tumor and covering ≥ 10% of the area tumors) and without EGFR or ALK tumor genomic aberrations.

First-line treatment in combination with bevacizumab, paclitaxel and carboplatin for adult patients with metastatic non-squamous NSCLC without EGFR or ALK tumor genomic aberrations.

First-line treatment in combination with paclitaxel associated with protein, and carboplatin for adult patients with metastatic non-squamous NSCLC without EGFR or ALK tumor genomic aberrations.

Treatment of adult patients with metastatic NSCLC who experience disease progression during or after platinum-containing chemotherapy. Patients with genomic aberrations of EGFR or ALK tumors should be monitored for disease progression on therapy approved for NSCLC with such aberrations before starting Tecentriq®.

Dext cell lung cancer:

First-line treatment in combination with carboplatin and etoposide for adult patients with advanced dead cell lung cancer (DCLC).

Hepatocellular carcinoma:

Treatment in combination with bevacizumab for patients with unresectable or metastatic hepatocellular carcinoma carcinoma who have not previously received systemic therapy.